Pune: ZYCOV-D, the first vaccine to be approved for use in children over the age of 12 in India, will also be available for private sector hospitals throughout the country.
The central supply principle in the ratio of 75:25 for public and private vaccination will still apply to this vaccine too.
“If there are buyers, up to 25 lakh doses of Zycov-D will be available for private school hospitals every month because the availability of the initial monthly vaccine will be 1 dose of crore,” NK Arora, chief downtown Covid-19 who worked the group of national technical advisory groups Immunization (Ntagi) to TOI on Sunday.
However, 75% of available doses will be reserved for adolescent vaccination that qualifies in public vaccination centers for free, Arora clarifies.
Zycov-D vaccine-free needle, which is produced by Zydus Cadila based in Ahmedabad, has received authorization of emergency use because it is given to children aged 12 years and over in India.
Three dose vaccines must be provided with a gap of 28 days between each dose.
Zycov-D will be introduced in the Covid Country Vaccination Program on October 20.
“The biggest obstacle or challenge about this vaccine is the slow production.
Initially, the manufacturer can only provide one dose of crore every month.
Private hospitals can get 25% of the monthly production of Zycov-D from the manufacturer,” Arora said.
However, he added that the private sector did not show much interest in the purchase of vaccines after the new guideline on the supply of the Covid-19 vaccine in the ratio of 75:25 came into force several months ago.
The Covid-19 vaccine manufacturer in India makes the central government get information about their production plan in advance.
This helps the government better plan procurement and distribution.
The center also knows about the demand for consolidation from the private sector, because the state government deposes demand and indicates it to the authorities.
Dhananjay Kelarm, Medical Director of Pune Deenanath Mangeshkar Hospital, “Private Hospitals will buy Zycov-D vaccines, but this time they will be careful in their approach.
Initially, purchases tend to be smaller to assess the response.
Again, costs Vaccines in private hospitals will also determine the absorption.
“Sanjay Lalwani, Medical Director of the Bharati Hospital in Pune, said,” The purchase of a private Zycov-D vaccine is likely to be slow.
This is a three-dose vaccine, therefore vaccination costs tend to be high which might also have an impact Negative purchases in the private sector.
“